Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X Syndrome

Trial Profile

A Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X Syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ganaxolone (Primary)
  • Indications Fragile X syndrome
  • Focus Proof of concept; Therapeutic Use
  • Acronyms GNX
  • Sponsors Marinus Pharmaceuticals
  • Most Recent Events

    • 28 Apr 2017 Status changed from active, no longer recruiting to completed,according to the results published in Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results assessing safety and efficacy presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Jun 2016 According to a Marinus Pharmaceuticals media release, the company in collaboration with University of California (UC) Davis and Antwerp University Hospital, is continuing to analyze the data and planning to submit the data in its entirety for presentation at the National Fragile X Conference in July.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top